FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
Benedikt Simbrunner(Austrian Academy of Sciences), Thomas Reiberger(ERN GUARD-Heart), Georg Semmler(University of Southern Denmark), Oleksandr Petrenko(Austrian Academy of Sciences), Benedikt Hofer(Austrian Academy of Sciences), Rodrig Marculescu(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Claudia Fuchs(Medical University of Vienna), Philipp Schwabl(Austrian Academy of Sciences), Mattias Mandorfer(Medical University of Vienna), Kerstin Zinober(Medical University of Vienna), Christian Datz(Paracelsus Medical University)
Cited by 19
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
|Gastroenterology|2014|563
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
|Annual Review of Pathology Mechanisms of Disease|2018|561
Pathophysiological mechanisms of liver injury in COVID‐19
|Liver International|2020|399